Gone to Pot: The Complex Relationship Between Cannabis, Cannabinoids…

UPMC

D. D'Souza

Clozapine REMS No More? FDA Panel Recommends to Eliminate the Program

Deanna Kelly

R. Love

Schizophrenia Awareness Day Series: Psychosis is Real, so is Recover…

2024 Mental Health Awareness Video Series

S. Chaudhry, A. Weiss

Conference Highlights: Trajectories of Daily Antipsychotic Use and W…

2024 Conference Highlights

T. Hajek

Antipsychotics in Early-Onset Psychosis

Stephen Grcevich

Year-in-Review Series: Cobenfy & The Schizophrenia Pipeline

Stephen Marder

Neurobiology of First Episode Psychosis

Institute of Mental Health Nottingham

D. Ongur

Conference Highlights: The Utilization of Long-Acting Injectable Ant…

2024 Conference Highlights

J. Kane

Conference Highlights: Beyond D2 blockers - New mechanistic approach…

2024 Conference Highlights

R. Mizrahi

Early Psychosis and the Psychosis Risk Syndrome: Current Knowledge, …

Daniel Mathalon

Year-in-Review Series: Schizophrenia 2024 - Ongoing Progress, Unmet …

Henry Nasrallah

Analysis of Claims Data Preceding the First Episode of Schizophrenia…

UPMC

K. Suh, T. Mayanil

Conference Highlights: The Impact of Early Adminstration of Long-Act…

2024 Conference Highlights

N. Pai

Conference Highlights: Schizophrenia and Psychosis Diagnosis and Tre…

2024 Conference Highlights

S. Galderisi

Conference Highlights: When the Patient Isn't Getting Better - A Psy…

2024 Conference Highlights

E. Plakun

Schizophrenia Awareness Day Series: The Many Etiologies of Schizophr…

2024 Mental Health Awareness Video Series

H. Nasrallah

Diagnostic Dilemmas and Challenging Differential Diagnoses in Neurop…

University of Miami

A. Bure-Reyes

Insights Into Muscarinic Agonists: A New Antipsychotic Class Potenti…

Jose Rubio

Year-in-Review Series: Recent Psychiatric Drug Approvals & Rejections

Richard Louis Price

M. Zachary Price

Schizophrenia Round Table - New Developments

Rakesh Jain